Further analysis from the Phase 3 ANDROMEDA study presented at the 2021 ASCO Annual Meeting also show doubling rates of organ response with no new safety signals The Janssen Pharmaceutical Companies
Curcumin Effect Explored In Amyloidosis by Karishma Abhishek on March 2, 2021 at 8:00 AM abnormal aggregation and deposition of proteins, known as amyloid fibrils in various tissues and organs, such as Alzheimer s disease, immunoglobulin light chain amyloidosis.
Earlier studies have revealed the role of curcumin in suppressing the aggregation and cytotoxicity of several amyloid proteins in vitro, such as amyloid ß (Aß), α-synuclein, transthyretin, and prion protein. The inhibition of Aß fibrils deposition by curcumin is also seen in the mouse model of Alzheimer s disease. Curcumin - a polyphenol compound produced by plants of the Curcuma longa species has several properties like anti-oxidation, anti-inflammatory, anti-cancer, and anti-amyloid properties. But the exact mechanism driving these action are not clear.
Curcumin is a polyphenol compound produced by plants of the Curcuma longa species and has been reported to have many physiological activities, which include anti-oxidation, anti-inflammatory, anti-cancer, and anti-amyloid properties.
email article
One theory for why the medications tested in heart failure with preserved ejection fraction (HFpEF) trials have not shown efficacy: inclusion of too many unrecognized cases of cardiac amyloidosis (CA). The specific hemodynamic and pathophysiological features of CA result in poor tolerance of heart failure medications and in worse outcomes compared with other causes of heart failure, according to Silvia Oghina, MD, of Hôpital Henri-Mondor in Créteil, France, and colleagues. Studies have shown CA in up to 29% of patients with HFpEF. This finding is unsurprising, as criteria used to diagnose HFpEF include the presence by echocardiography of left ventricular hypertrophy with left atrial enlargement and/or diastolic dysfunction, which are typical features of CA, they wrote in a state-of-the-art paper published online in
email article
Novel RNAi drug vutrisiran met its primary endpoint in topline results from the phase III HELIOS-A trial in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy and improved the exploratory cardiac biomarker endpoint as well, Alnylam Pharmaceuticals announced.
Mental health disorders among heart attack patients have increased in the last decade, researchers warned in the
American Journal of Preventive Cardiology. Natriuretic peptide deficiency might explain why some confirmed heart failure and cardiac dysfunction patients have unexpectedly low B-type natriuretic peptide levels. (
JACC: Heart Failure)
Women taking a statin during chemotherapy for early-stage breast cancer were half as likely to need emergency heart failure care in the subsequent 5 years. (